#119 ROLE OF PROSTAGLANDIN E2 AND EP-1 RECEPTOR ON DETRUSOR OVERACTIVITY IN SPINAL CORD INJURY
Masunaga K1, Yoshida M1, Inadome A1, Matsumoto K1, Yono M1, Kai N1, Sugiyama Y1, Honda J1, Maeda Y1, Satoji Y1, Takahashi W1, Ueda S1 1. Department of Urology, Graduate School of Medical Sciences, Kumamoto University
#120 Mutation of β3-Adrenoceptor Gene: A Genetic Marker for Overactive Bladder PRIZE AWARD: Best Non-Clinical Abstract
Honda K1, Nomiya M1, Shishido K1, Yoshimura Y1, Yamaguchi O1 1. Fukushima Medical University
#121 Comparative evaluation of human mucosa and detrusor muscarinic receptor binding by anticholinergic agents in the treatment of overactive bladder
Oki T1, Luvsandorj O1, Suzuki K1, Kageyama A1, Otsuka A2, Shinbo H2, Ozono S2, Yamada S1 1. Department of Pharmacokinetics and Pharmacodynamics, Sch of Pharm Sci, University of Shizuoka, 2. Department of Urology, Hamamatsu University School of Medicine
#122 Time-dependent changes in nitric oxide synthase isoforms in the spinal cord in a rat model of detrusor overactivity induced by bladder irritation
Masuda H1, Chancellor M2, Kihara K1, Miguel F3, de Groat W4, Yoshimura N2 1. Department of Urology, Tokyo Medical and Dental University, 2. Department of Urology, University of Pittsburgh, 3. Departement of Urology, Universty of Pittsburgh, 4. Department of Pharmacology, University of Pittsburgh
#123 Solifenacin Improved Warning Time Significantly Compared to Placebo in Patients with Overactive Bladder
Toglia M1, Andoh M2, Hussain I2 1. Urogynecology Associates of Philadelphia, Media, PA, 2. Astellas Pharma, Inc., Deerfield, IL
#124 The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB)
Olshansky B1, Foote J2, Arguinzoniz M3, Lheritier K3, Quebe-Fehling E3, Steel M3 1. University of Iowa Hospitals, Iowa, IA, USA, 2. Midtown Urology and Surgical Center, Atlanta, GA, USA, 3. Novartis Pharma AG, Basel, Switzerland
#125 Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: analysis of results from a 2-year, open-label extension study
Dwyer P1, Lheritier K2, Steel M2 1. Mercy Hospital for Women, Melbourne, Australia, 2. Novartis Pharma AG, Basel, Switzerland
#126 EFFICACY OF ANTIMUSCARINICS IN WOMEN WITH ANTERIOR VAGINAL WALL PROLAPSE: IS IT THE SAME?
Salvatore S1, Serati M1, Zanfrà M1, Cromi A1, Ghezzi F1, Bolis P1 1. Clinica ostetrica e Ginecologica, Università dell'Insubria
#127 Duloxetine Compared with Placebo for the Treatment of Women with Symptoms of Bladder Overactivity
Bump R1, Steers W2, Herschorn S3, Kreder K4, Moore K5, Strohbehn K6, Yalcin I1 1. Lilly Research Laboratories, 2. University of Virginia, 3. University of Toronto, 4. University of Iowa, 5. St George Hospital, 6. Dartmouth-Hitchcock Medical Center
#128 Histological changes in the human bladder urothelium and suburothelium following injections of Botulinum neurotoxin type A (BoNT/A) for the treatment of neurogenic versus idiopathic detrusor overactivity (NDO/IDO)
Apostolidis A1, Jacques T S 2, Freeman A 3, Ghazi-Noori S1, Kalsi V4, Popat R4, Gonzales G4, Beckett A1, Datta S4, Elneil S4, Dasgupta P5, Fowler C J 4 1. Institute of Neurology, UCL, London, 2. Institute of Child Health, UCL, london, 3. Department of Histopathology, UCLH, london, 4. The National Hospital for Neurology and Neurosurgery, UCLH, London, 5. Guy's and St. Thomas's Hospitals and The National Hospital for Neurology and Neurosurgery, UCLH, Lon
#129 The Use of Intravesical Botulinum Toxin in Overactive Bladder Syndrome: A Systematic Review.
Duthie J1, Wilson D I2, Herbison P3, Wilson P D3 1. Palmerston North Hospital, 2. City Hospital Nottingham, 3. Otago University
#130 A double-blind, placebo controlled study investigating efficacy of botulinum toxin type A (Dysport®) in MS related overactive bladder syndrome (OAB): Provisional 36 week results.
Finney S1, Patrick K1, Stewart L1 1. Western General Hospital